Royalty Pharma Plc (RPRX NASDAQ) stock market data APIs
$40.3019
0.13(0.3%)
as of January 14, 2026
Try our APIs with
free plan!
Royalty Pharma Plc Financial Data Overview
Price chart is built with
Anychart
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Prev. Close
40.3019
Open
40.4338
High
40.6394
Low
40.1602
52 wk Range
28.9944-41.7
Market Cap
23 449 M
P/E Ratio
22.9771
Shares Outstanding
427 M
Revenue
2 350 M
EPS
1.17
Dividends (Yield)
0.0216
Beta
0.425
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Royalty Pharma Plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Royalty Pharma Plc data using free add-ons & libraries
Get Royalty Pharma Plc Fundamental Data
Royalty Pharma Plc Fundamental data includes:
- Net Revenue: 2 350 M
- EBITDA: 1 498 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 1.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Royalty Pharma Plc News
New
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight
DelveInsight Business Research LLP The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapie...
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up to $500 million to accelerate the development of Teva’s anti-IL-15 antibo...
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Royalty Pharma PLC (RPRX) : Free Stock Analys...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
Royalty Pharma plc Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership with announced transactions of $4.7 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
